Tools and  Technologies for Breakthrough in

Heart Therapies


TECHNOBEAT is rooted in extensive, interdisciplinary research of basic and applied scientists at the LEBAO and clinicians at the HTTG (Department of Cardiothoracic, Transplantation and Vascular Surgery) on the MHH campus. Substantial recent progress in i) human induced pluripotent stem cell (hiPSC) reprogramming and tailored genetic engineering (RG Martin), ii) novel methods for hiPSC mass production in controlled bioreactors including cardiac (RG Zweigerdt) and endothelial differentiation (RG Olmer), as well as iii) excellent animal models of heart failure and cell therapies (RGs Haverich, Cebotari, Martens) paved the way to the EU Horizon2020 funded, trans European Network TECHNOBEAT, which is coordinated at the LEBAO. Project details can be found here.